Interviews

Natalie Dickson, MD, president and chief strategy officer of Tennessee Oncology, discusses Tennessee Oncology's role in the discussion to reform 340B.

During the COVID-19 pandemic, there has been a lot of experimentation with new technologies for remote patient monitoring (RPM) to improve adherence and survival, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses safety findings of the TOPAZ-1 trial.

Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.

On this episode of Managed Care Cast, Marcelina Jasmine Silva, DO, discusses her recent work on prolonged cessation of chronic opioid analgesic therapy among patients with chronic noncancer pain.

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.

Steven Feldman, MD, PhD, professor of dermatology at Wake Forest School of Medicine, discusses what makes clascoterone (Winlevi) different from past acne treatments.

On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.

Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health (GPBCH), outlines how Wilmington, Delaware, went about implementing the Diabetes Prevention Program.

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, and current president of the Community Oncology Alliance (COA), speaks on what he’s looking forward to for his first in-person Community Oncology Conference as COA president.

Judith Lavrich, MD, and Jordan Hamburger discuss the need for more research on the impact of screen time on eye health following their study on virtual school and children's eyesight.

William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, discuss how respiratory syncytial virus (RSV) affects different age groups.

Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss the results of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.

Ted Mikuls, MD, MSPH, Stokes-Shackleford Professor of Rheumatology, vice chair for research, internal medicine, at the University of Nebraska, discusses findings on urate-lowering therapy and the lack of regional data on gout-related lower-extremity amputation.

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses the addition of durvalumab to a chemotherapy regimen of gemcitabine and cisplatin for biliary duct cancer.

Julie M. Reed, the new executive director of the Biosimilars Forum, offers her opinion on how interchangeability will impact US biosimilar uptake now that the FDA has given the designation to 2 biosimilars.

Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health (GPBCH), describes how the organization first became involved with the National Diabetes Prevention Program.

David Ramsey, MD, PhD, MPH, outlines why patients with diabetes should undergo regular eye examinations.

Stephen Schleicher, MD, MBA, chief medical officer of Tennessee Oncology, discusses the practice's plans to continue providing quality oncology care to its patients after the end of the Oncology Care Model (OCM).

Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, discusses interventions and treatments that could prevent lower extremity amputation for people with gout.

Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.

Colette Romero, an advocate for eosinophilic esophagitis (EoE) awareness, discusses the steps her family went through to find a therapy plan that worked for her son.

Robert Sidbury, MD, MPH, chief of the Division of Dermatology at Seattle Children's Hospital, discusses risk factors involved in the pathogenesis of atopic dermatitis and several diagnostic methods.

James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, lists potential solutions to bolster ophthalmic trauma care in the United States.

Dennis P. Scanlon, PhD, professor of health policy and administration at Pennsylvania State University and editor-in-chief of The American Journal of Accountable Care, discusses his 2021 end-of-year letter calling on health system leaders to learn and innovate in real time.

Robert Gabbay, MD, PhD, of the American Diabetes Association, explains why a section on chronic kidney disease management was added to the ADA's 2022 standard of care guidelines.

William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how the COVID-19 pandemic has had an impact on the seasonality of respiratory syncytial virus (RSV).

Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, discusses areas where low-value care is more prevalent and the shift to high-value care.